0001209191-22-039324.txt : 20220624
0001209191-22-039324.hdr.sgml : 20220624
20220624184353
ACCESSION NUMBER: 0001209191-22-039324
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220622
FILED AS OF DATE: 20220624
DATE AS OF CHANGE: 20220624
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Colowick Alan
CENTRAL INDEX KEY: 0001316163
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38800
FILM NUMBER: 221041273
MAIL ADDRESS:
STREET 1: C/O THRESHOLD PHARMACEUTICALS, INC.
STREET 2: 1300 SEAPORT BOULEVARD, 5TH FLOOR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Harpoon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001708493
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473458693
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 OYSTER POINT BOULEVARD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-7400
MAIL ADDRESS:
STREET 1: 131 OYSTER POINT BOULEVARD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-22
0
0001708493
Harpoon Therapeutics, Inc.
HARP
0001316163
Colowick Alan
C/O HARPOON THERAPEUTICS, INC.
131 OYSTER POINT BOULEVARD, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Director Stock Option (Right to Buy)
2.01
2022-06-22
4
A
0
10167
0.00
A
2032-06-21
Common Stock
10167
10167
D
Director Stock Option (Right to Buy)
2.01
2022-06-22
4
A
0
28571
1.40
A
2032-06-21
Common Stock
28571
28571
D
The stock option will fully vest and become exercisable on June 21, 2023, subject to the continuous service of the Reporting Person with the Issuer on such date.
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $40,000 ("Election Option").
One-half of the Election Option vested and became exercisable on June 22, 2022, and 25% of each Election Option will vest and become exercisable on each of September 30, 2022 and December 31, 2022, subject to the continuous service of the Reporting Person with the Issuer through each vesting date.
/s/ Alan Colowick by Georgia Erbez, Attorney-in-Fact
2022-06-24